Clinical Trial

Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma

Name: Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma — clinical trial record (NCT07614035)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASCLEPIO

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant treatment toxicity.

Trial Details

NCT Number	NCT07614035
Lead Sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions	Non-Hodgkin Lymphoma
Enrollment	70 participants
Start Date	2026-06-30
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-29